Loading data for ADIL — first visit, this takes a few seconds.

알림

Adial Pharmaceuticals Inc... (ADIL)

NasdaqCM: ADIL · 실시간 가격 · USD

4.39

+0.08 (1.86%)

종가 기준: Aug 18, 2026, 3:59 PM

1.86% (1D)

매수호가	4.57
시가총액	14.31M
매출 (ttm)	n/a
순이익 (ttm)	-57.8M
베타	n/a
EPS (ttm)	-5.39
P/E (ttm)	n/a
선행 P/E	-0.73
P/B (ttm)	-0.37
P/S (ttm)	n/a
Earnings Date	n/a

매도호가	3.08
거래량	51,676
평균 거래량 (20일)	458,140
시가	4.35
전일 종가	4.31
일중 범위	4.26 - 4.63
52주 범위	1.31 - 10.75
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ADIL 소개

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 27, 2018

직원 수 5

상장 거래소 NasdaqCM

티커 ADIL

웹사이트 https://www.adial.com

전체 기업 정보

재무 실적

2025년 Adial Pharmaceuticals의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -7.98M로, -39.56% 감소했습니다.

재무제표

어닝 서프라이즈

Adial Pharmaceuticals가 May 8, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -1.48 예상치 상회 0.77, 및 82.59% 전년 대비 성장.

뉴스

2개월 전 · MT Newswires

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street

2개월 전 · Stocktwits

ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally

Adial on Thursday announced that it has bought privately held Azora Therapeutics.

7개월 전 · Zacks

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

10개월 전 · The Fly

CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls

11개월 전 · Benzinga

Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Tuesday received the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held in July. The minute...

2 페이지 중 1

Adial Pharmaceuticals Inc... (ADIL)